Clinical Trial Update: Trial of Screening for ALOA-IgG AtheroAbzyme Test [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the ALOA-IgG AtheroAbzyme Test for screening in patients with myocardial ischemia and acute coronary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Ischemia

Snippet

Sponsor: Omicron Pharmaceuticals | Conditions: Myocardial Ischemia, Acute Coronary Syndrome | Phase 3 | Status: COMPLETED